About OHR Pharmaceutical, Inc.

Ohr Pharmaceutical, Inc. (NasdaqCM:OHRP) is a biotechnology company focused on developing novel therapies for underserved areas in ophthalmology. The company’s primary area of interest is the treatment of retinal disorders, especially wet age-related macular degeneration (wet AMD), which remains a leading cause of vision loss in adults over 50. Ohr’s research and development programs have centered around creating alternatives to invasive treatments currently used in clinical settings.

One of Ohr’s key investigational platforms involves sustained-release drug delivery for anti-VEGF therapy. Current standard treatment for wet AMD often requires monthly injections directly into the eye, which can be uncomfortable, high-risk, and difficult to maintain over time. Ohr’s approach aims to reduce the frequency of these injections by offering long-acting formulations that deliver therapeutic agents in a controlled, consistent way. This strategy is intended to maintain visual outcomes while easing the treatment burden on patients and physicians.

The company has also explored small molecule drug candidates that can target multiple pathways associated with ocular inflammation and degeneration. The development process includes preclinical pharmacology, formulation engineering, and human clinical trials in compliance with FDA and international regulatory standards. Ohr works with ophthalmologists, retinal specialists, and research centers to structure its study protocols based on real-world clinical demands.